---
title: "Suzhou Wangshan Wangshui Biomedicine Co., Ltd. plans to price its Hong Kong IPO at HKD 33.37 per share"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/264129175.md"
description: "According to reports, Suzhou Wangshan Wangshui Biomedicine Co., Ltd. plans to price its Hong Kong IPO at HKD 33.37 per share. (Sina Finance)"
datetime: "2025-11-04T03:16:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264129175.md)
  - [en](https://longbridge.com/en/news/264129175.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264129175.md)
generator: "portal-rs"
---

# Suzhou Wangshan Wangshui Biomedicine Co., Ltd. plans to price its Hong Kong IPO at HKD 33.37 per share

According to reports, Suzhou Wangshan Wangshui Biomedicine Co., Ltd. plans to price its Hong Kong IPO at HKD 33.37 per share. (Sina Finance)

### Related Stocks

- [399441.CN](https://longbridge.com/en/quote/399441.CN.md)

## Related News & Research

- [Vishnusurya Projects and Infra's (NSE:VISHNUINFR) Weak Earnings May Only Reveal A Part Of The Whole Picture](https://longbridge.com/en/news/305559929.md)
- [Pondy Oxides And Chemicals Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected](https://longbridge.com/en/news/305560101.md)
- [RioCan Real Estate Investment Trust (TSX:REI.UN) Expands Its Buyback Program, Is It Still Undervalued?](https://longbridge.com/en/news/305557624.md)
- [Kava Lend loses roughly $3.8 million to hack, sending KAVA token down nearly 40%](https://longbridge.com/en/news/305556359.md)
- [Servier Presents Updated Four-Year Results from Phase 2 FIREFLY-1 Study of OJEMDA® (tovorafenib) in Pediatric Low-Grade Glioma (pLGG) at SNO 2026](https://longbridge.com/en/news/305554906.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**